Lexaria Bioscience Corp (OTCMKTS:LXRP) has offered an update regarding a previously announced antiviral research work and unveiled a new research project with possible COVID-19 applications.
Lexaria to commence human trials for antiviral drugs
In March this year, the company announced plans to carry out a pilot human pharmacokinetic exploratory trial in healthy participants of antiviral drugs. The drugs had been evaluated previously against other coronavirus varieties by comparing the company’s DehydraTECH™ formulations and controls without the tech. The approval from the ethics board, which was needed as the first step in the pilot study, has been receiving other governmental regulatory approval.
In conjunction with the study, the company has announced the launch of another separate rodent antiviral study evaluating pharmacokinetic benefits from the use of the DehydraTECH. They will evaluate the technology in delivering representative drugs from two antiviral drug classes under study against COVID-19. So far, the company has processed the drugs with DehydraTECH and sent them to the facility for further testing.
Chris Bunka, the CEO of Lexaria, said that they are delighted to progress towards the pilot human study using the DehydraTECH platform in the delivery of antiviral drugs. He added that the company is continuing the process of regulatory approval to advance the study.
Lexaria receives an order commitment of 4.4 CBD servings
Recently the company announced that it had received purchase order commitments of around 4.4 million CBD servings of the DehydraTECH™ enabled CBD powders. The orders will be processed in the fiscal Q1 2021, which will end on November 30, 2020. The company has also received verbal requests from current licensees to ready its facility to produce around 56 million servings during the 2021 calendar year. However, the indicative orders do not include any possible demand expected from new clients.
In fiscal Q4 2020, the company processed 1.2 million CBD servings and around 0.7 million servings in Q3, which ended on May 31. A serving ranges between 10mg and 20mg of CBD each, and it uses the proprietary DehydraTECH.
 Receives Approval For Human Study With DehydraTECH In Delivery Of Antiviral Drugs){kind=link}